Talecris Biotherapeutics Offers $550M In Senior Notes
Talecris will use the offering's proceeds to repay first- and second-lien term loans, repay some of the borrowings under its revolving credit facility, and pay related fees and expenses, the company said in a statement Tuesday.
The law firms representing Talecris in this transaction, if any, were not available at the time of publication.
On Oct. 6, Talecris closed its initial public offering of shares...
To view the full article, register now.